Myriad Genetics announces cancer research collaboration with Janssen

Dec. 12, 2013

Companion diagnostics marches on: Myriad Genetics, Inc., has announced that Janssen Research & Development, LLC, will use Myriad's BRACAnalysis test in connection with its Phase 3 clinical trial of Yondelis (trabectedin) in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers.

“We are delighted to be collaborating with Janssen and applying our more than 20 years of BRCA-testing experience to help advance clinical cancer research,” says Mark C. Capone, president of Myriad Genetics Laboratories.

Myriad represents this strategic partnership as a step toward an era of precision medicine and custom healthcare. Read more about BRACAnalysis.